NGM120 was developed by NGM (USA), ponsegromab by Pfizer (Pfizer), AV‐380 by AVEO (AVEO), CTL‐002 by CataLYM (Germany), and G15A by our research group.[7, 37] All of these agents block GDF15 signaling via monoclonal antibodies, thereby promoting the killing of tumor cells by immune cells and improving cachexia in patients with advanced tumors. The gene discussed is GDF15; the disease is neoplasm.